In the meantime, Exane BNP Paribas initiated its Sanofi ADR [SNY] rating to an Outperform in a research note published on April 15, 2025; the price target was $65. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in late March with a ‘”a Neutral”‘ rating. Deutsche Bank also remained covering SNY and has increased its forecast on January 30, 2025 with a “Hold” recommendation from previously “Sell” rating. Argus maintained its rating on July 26, 2024. It rated SNY as “a Buy”.
Price Performance Review of SNY
On Tuesday, Sanofi ADR [NASDAQ:SNY] saw its stock jump 1.81% to $51.85. Over the last five days, the stock has gained 0.02%. Sanofi ADR shares have risen nearly 7.51% since the year began. Nevertheless, the stocks have risen 14.23% over the past one year. While a 52-week high of $60.12 was reached on 03/10/25, a 52-week low of $45.80 was recorded on 04/09/25. SMA at 50 days reached $54.80, while 200 days put it at $52.92.
Levels Of Support And Resistance For SNY Stock
The 24-hour chart illustrates a support level at 51.31, which if violated will result in even more drops to 50.78. On the upside, there is a resistance level at 52.32. A further resistance level may holdings at 52.79. The Relative Strength Index (RSI) on the 14-day chart is 44.62, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 48.57%. Stochastics %K at 43.70% indicates the stock is a holding.
How much short interest is there in Sanofi ADR?
A steep rise in short interest was recorded in Sanofi ADR stocks on 2025-03-31, dropping by -1.42 million shares to a total of 4.0 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 5.42 million shares. There was a decline of -35.46%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 23, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Equal-weight”‘ rating along with a $55 price target.
